Complete coverage on

Vytorin

Latest Stories

Help me understand my cholesterol drugsupdated: Thu Jan 28 2010 12:38:00

Hi, I'm 55 and have high cholesterol. I've been on Lipitor, Zocor and Provacol. They have tested me several times in recent years, and the statin drugs are messing up my liver enzymes. My new doctor is planning on putting me on Zetia. Now I'm hearing there are concerns about Zetia. Do you know what they are concerned about?

Half avoid rotavirus vaccineupdated: Mon Apr 21 2008 13:33:00

CNN's Dr. Sanjay Gupta reports on the CDC's recommendation that parents vaccinate for rotavirus.

CNNMoney: Merck profit strong, sales weakupdated: Mon Apr 21 2008 13:33:00

Merck said Monday its first-quarter earnings jumped due to income from a partnership, but the drugmaker's sales showed just a slight gain.

CNNMoney: Schering stock jumps on job cutsupdated: Thu Apr 03 2008 12:44:00

Schering-Plough's stock jumped Thursday, after the drugmaker's chief executive announced he would cut 10% of its staff.

CNNMoney: Stocks up day, down quarterupdated: Mon Mar 31 2008 17:55:00

Falling oil prices helped lift stocks Monday, at the end of an otherwise abysmal quarter on Wall Street, marred by fears of a recession amid the housing crisis and credit market fallout.

CNNMoney: Stocks set for mixed openupdated: Mon Mar 31 2008 08:39:00

U.S. stocks looked set for a mixed start on the last day of the quarter, as investors await a Bush administration plan aimed at overhauling regulation on Wall Street amid a meltdown in the financial sector.

CNNMoney: Schering stock jumps on earnings winupdated: Tue Feb 12 2008 12:00:00

Schering-Plough may have lost billions of dollars in the fourth quarter from an acquisition, but its stock jumped Tuesday as the drugmaker's earnings without charges beat expectations.

Fortune: Schering CEO in the hot seatupdated: Mon Feb 11 2008 14:00:00

As Schering-Plough unveils full-year financial results for 2007 tomorrow, CEO Fred Hassan is likely to be peppered with questions about how he managed a recently released study of embattled cholesterol drug, Vytorin.

Fortune: Cholesterol skeptics have their dayupdated: Wed Feb 06 2008 16:46:00

Is low cholesterol the pathway to a healthier heart? That's certainly what most medical experts - and their patients - have assumed for the last 30 years or so. But a recently-released study of Merck and Schering-Plough's cholesterol-lowering drug, Vytorin, is giving new voice to medical critics who have groused for decades about the questionable benefit of using medications to lower cholesterol and thereby prevent heart disease.

CNNMoney: Big Pharma's leaky pipelineupdated: Fri Feb 01 2008 14:45:00

After the latest round of mixed earnings from the biggest players in pharma and biotech, companies are hampered by a frustrating dynamic: a product mix that isn't strong enough to match an exodus of blockbusters.

CNNMoney: Merck's earnings pop, but shares slumpupdated: Wed Jan 30 2008 11:45:00

Merck & Co. reported a surge in fourth-quarter operating earnings Wednesday that exceeded analysts' estimates, but shares slumped in early trading.

Marijuana vending machinesupdated: Mon Jan 28 2008 16:29:00

A herbal nutrition center will allow patients to get prescription marijuana from a vending machine. Affiliate KCAL reports.

CNNMoney: Big Pharma: back from a rough yearupdated: Mon Jan 28 2008 16:29:00

More big drugmakers are on tap this week to report strong 2007 earnings, but that's because 2006 was an easy act to follow.

CNNMoney: Bulls throw in the towelupdated: Fri Jan 25 2008 17:57:00

Stocks tanked Friday, as investors abandoned ship after a two-session rally that followed a tough start to the new year.

Can surgery cure diabetes?updated: Fri Jan 25 2008 17:08:00

CNN's Dr. Sanjay Gupta examines recent studies that show Type 2 diabetes could vanish after bariatric surgery.

CNNMoney: FDA scrutinizes Vytorinupdated: Fri Jan 25 2008 17:08:00

Government regulators said Friday they are analyzing recent study results regarding cholesterol drug Vytorin, but that it's too early to tell whether it will take any regulatory action.

CNNMoney: Wall Street slammed againupdated: Thu Jan 17 2008 12:37:00

Stocks tanked Thursday afternoon after Federal Reserve Chairman Ben Bernanke urged lawmakers to enact a fiscal stimulus plan soon to help consumers and the economy.

CNNMoney: Schering stock nearly crawls out of its holeupdated: Wed Jan 16 2008 17:27:00

Schering-Plough's stock almost crawled out of its hole Wednesday after a two-day lashing sparked by the results of a cholesterol drug trial, but the shares fell just before the market's close.

Cholesterol drug in doubtupdated: Wed Jan 16 2008 17:27:00

A study suggests the cholesterol drug Vytorin may not help arteries more than a generic. CNN's Dr. Sanjay Gupta reports.

Time.com: Is Vytorin a Failure?updated: Tue Jan 15 2008 18:00:00

Surprising study results show that the popular heart drug doesn't live up to its claims -- and three new trials are now under way

Saving money on prescriptionsupdated: Mon Jan 14 2008 10:18:00

Dr. Sanjay Gupta talks about saving money on prescription drugs with Open House host Gerri Willis.

Stop snoring!updated: Tue Oct 02 2007 14:12:00

England's government is set to pay for pressurized air masks that combat sleep apnea. CNN's Alphonso Van Marsh reports.

CNNMoney: Schering pushing hard to diversifyupdated: Tue Oct 02 2007 14:12:00

Drugmaker Schering-Plough is a favorite of analysts and investors these days. It's no wonder: The company's flagship product, the cholesterol-fighting Vytorin, is breaking sales records and faces relatively little risk from cheaper generic versions from rivals.

CNNMoney: Schering-Plough profits riseupdated: Sun Jul 22 2007 21:50:00

Schering-Plough Corp. said Monday that second-quarter earnings rose sharply, fueled by growing demand for its Zetia and Vytorin cholesterol drugs and treatments for arthritis and allergies.

CNNMoney: Pity the poor pharmaceutical sales repupdated: Mon Apr 02 2007 15:33:00

It's hard out there for drug sales reps--particularly if they work in places where gaining access to doctors is becoming increasingly difficult.

Fortune: Serwer: 2 winners and a very soft shoeupdated: Wed Aug 30 2006 08:19:00

All this reading of the tea leaves of Fed meeting minutes makes my brain hurt! I mean talk about white noise. Here's a question: Will the action pick up after Labor Day?

CNNMoney: Schering-Plough's cholesterol problemupdated: Tue Aug 08 2006 09:46:00

Drugmaker Schering-Plough may have wowed investors with strong second-quarter earnings - but the company has a cholesterol problem.

CNNMoney: Vytorin is better than Crestor, says study from Merck, Schering-Ploughupdated: Mon Jun 19 2006 06:00:00

Merck and Schering-Plough announced a study on Sunday showing that their combination drug Vytorin is better at lowering cholesterol than competing drug Crestor from AstraZeneca.

CNNMoney: New salvo in cholesterol drug warupdated: Fri Jun 09 2006 18:41:00

Merck and Schering-Plough fired a shot across Pfizer's bow in the battle for control of the lucrative $25 billion cholesterol market with a new study saying their product is better for diabetics.

CNNMoney: Schering-Plough's big bet against Pfizerupdated: Wed Mar 15 2006 10:12:00

Schering-Plough, once the troubled child of the drug industry, is making a comeback with a hot new drug.

CNNMoney: Merck claims Vytorin beats Zocorupdated: Mon Mar 13 2006 08:13:00

A new study shows that Vytorin, a cholesterol drug from Merck and Schering-Plough that combines Zocor and Zetia, significantly reduces cholesterol when compared to Zocor alone, the company said.

CNNMoney: Vytorin outsells rival cholesterol drugsupdated: Tue Jul 26 2005 13:19:00

Vytorin, a relatively new cholesterol-blocking drug from Merck and Schering-Plough, has outpaced sales of a blockbuster rival, according to a report Monday from Friedman, Billings, Ramsey & Co.

CNNMoney: Vytorin sales rise during debut year.updated: Mon Jun 20 2005 13:57:00

Sales for Vytorin, a cholesterol-treating combination produced by Merck and Schering-Plough, have grown since its market debut last summer, but the drug's real test lies ahead, analysts say.

We recommend